Penetration of ravuconazole, a new triazole antifungal, into rat tissues

Chemotherapy

Volumn 48, Issue 1, 2002, Pages 7-9

  Mikamo, Hiroshige ^a   Yin, Xiang Hua ^a   Hayasaki, Yoh ^a   Shimamura, Yoshiko ^b   Uesugi, Keizo ^b   Fukayama, Nobuyuki ^b   Satoh, Masaru ^b   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Deep seated fungal infection; Ravuconazole (BMS 207147, ER 30346)

Indexed keywords

ANTIFUNGAL AGENT; ETHER; RAVUCONAZOLE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPERGILLUS; CANDIDA; CONTROLLED STUDY; CRYPTOCOCCUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; LUNG; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; UTERUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HALF-LIFE; LUNG; RATS; SPECIFIC PATHOGEN-FREE ORGANISMS; THIAZOLES; TRIAZOLES; UTERUS;

EID: 0036126393     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048580     Document Type: Article

References (8)

1. Penetration of oral fluconazole into gynecological tissues
2. Antifungal agents: Chemotherapeutic targets and immunologic strategies
3. New antifungal agents
4. Antifungal therapy and new azole compound
5. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
6. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
7. The kinetics of ketoconazole in animals and man
8. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans